Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Heptares Therapeutics has struck deals with two companies hoping to tap into its G protein-coupled receptor (GPCR) expertise. Heptares and Pfizer will work together to develop drugs targeting up to 10 GPCRs, with the biotech earning up to $189 million per target. Pfizer will also take a stake worth $33 million in Heptares’s parent company, Sosei. Separately, Teva Pharmaceutical Industries will pay $10 million for the rights to Heptares’s small-molecule antagonists of a GPCR protein called CGRP for the treatment of migraines. Teva says the Heptares molecules will complement its TEV-48125, an anti-CGRP antibody.
This article has been sent to the following recipient: